Sanofi SA (NYSE:SNY) saw some unusual options trading on Tuesday. Investors purchased 651 put options on the company. This is an increase of 666% compared to the typical daily volume of 85 put options.
A number of brokerages have recently issued reports on SNY. Sanford C. Bernstein reissued a “market perform” rating and issued a $45.00 price objective (down from $50.00) on shares of Sanofi in a research note on Thursday, February 8th. ValuEngine downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research downgraded Sanofi from a “hold” rating to a “sell” rating in a research note on Wednesday, February 14th. Bank of America downgraded Sanofi from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 6th. Finally, TheStreet downgraded Sanofi from a “b-” rating to a “c+” rating in a research note on Tuesday, February 13th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $49.33.
A number of institutional investors have recently modified their holdings of the stock. Cambridge Investment Research Advisors Inc. increased its position in Sanofi by 11.2% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 30,040 shares of the company’s stock valued at $1,292,000 after buying an additional 3,026 shares in the last quarter. Sawtooth Solutions LLC bought a new stake in Sanofi in the 4th quarter valued at about $355,000. We Are One Seven LLC bought a new stake in Sanofi in the 4th quarter valued at about $160,000. Banco de Sabadell S.A bought a new stake in Sanofi in the 4th quarter valued at about $792,000. Finally, Schafer Cullen Capital Management Inc. increased its position in Sanofi by 2.9% in the 4th quarter. Schafer Cullen Capital Management Inc. now owns 1,107,266 shares of the company’s stock valued at $47,612,000 after buying an additional 31,209 shares in the last quarter. 8.94% of the stock is owned by institutional investors and hedge funds.
Sanofi (NYSE:SNY) last issued its earnings results on Wednesday, February 7th. The company reported $0.62 EPS for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.07). Sanofi had a net margin of 23.25% and a return on equity of 24.30%. The firm had revenue of $8.69 billion during the quarter, compared to the consensus estimate of $8.65 billion. During the same period in the previous year, the firm earned $1.25 earnings per share. The business’s quarterly revenue was down 2.1% on a year-over-year basis. equities analysts anticipate that Sanofi will post 3.36 earnings per share for the current fiscal year.
The company also recently announced an annual dividend, which will be paid on Monday, June 4th. Investors of record on Thursday, May 10th will be given a $1.8609 dividend. This represents a yield of 4.72%. This is a positive change from Sanofi’s previous annual dividend of $1.58. The ex-dividend date of this dividend is Wednesday, May 9th. Sanofi’s payout ratio is presently 45.27%.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.